The role of ets transcriptional regulation in hormone sensitive and refractory prostate cancer

Open Cancer Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 40-48

  Turner, David P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Androgen deprivation therapy; Androgen receptor; ETS factors; Hormonal regulation; Hormone refractory prostate cancer; Prostate cancer; Transcription

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; FLUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERSTITIAL COLLAGENASE; MASPIN; MATRILYSIN; MATRIX METALLOPROTEINASE; NUCLEAR RECEPTOR COREPRESSOR; PREDNISONE; PROTEIN BCL 2; PROTEIN FOS; SURVIVIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELF 1; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX1; UNINDEXED DRUG; UROKINASE; UVOMORULIN; VIMENTIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CASTRATION; DRUG TARGETING; GENE EXPRESSION; HORMONE RESPONSIVE ELEMENT; HORMONE SENSITIVITY; HUMAN; ORCHIECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

EID: 78249248376     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010040     Document Type: Article

References (81)

1. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-433.
2. Li JJ, Li SA, Mohla S, Rochefort H, Maudelonde T. Hormonal carcinogenesis V. Preface. Adv Exp Med Biol 2008; 617: ix-x
3. Dunn BK, Ford LG. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prev 2007; 16: 232-242.
4. Heidenreich A, Aus G, Bolla M, et al.[EAU guidelines on prostate cancer]. Actas Urol Esp 2009; 33: 113-126.
5. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
6. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605.
7. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008; 9: 211-228.
8. Chang SS. Treatment options for hormone-refractory prostate cancer. Rev Urol 2007; 9 (Suppl 2): S13-18.
9. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
10. Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer 2007; 96: 970-979.
11. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
12. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
13. Golias C, Iliadis I, Peschos D, Charalabopoulos K. Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol 2009; 31: 3-8.
14. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-2478.
15. Turner DP, Findlay VJ, Moussa O, Watson DK. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem 2007; 102: 549-559.
16. Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 2008; 8: 33-42.
17. Seth A, Catzavelos C, Vary C, Ascione R. ETS transcription factors and targets in tumour invasion, angiogenesis and bone metastasis. Expert Opin Ther Targets 2001; 5: 87-107.
18. Hsu T, Trojanowska M, Watson DK. Ets proteins in biological control and cancer. J Cell Biochem 2004; 91: 896-903.
19. Alipov G, Nakayama T, Ito M, et al. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 2005; 46: 202-208.
20. Watabe T, Yoshida K, Shindoh M, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998; 77: 128-137.
21. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003; 2: 29.
22. Sementchenko VI, Watson DK. Ets target genes: past, present and future. Oncogene 2000; 19: 6533-6548.
23. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003; 63: 4626-31.
24. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 2007; 102: 19-30.
25. Gu X, Zerbini LF, Otu HH, et al. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67: 4219-4226.
26. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 2008; 19: 3745-3757.
27. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007; 67: 1618-1625.
28. Ghadersohi A, Odunsi K, Lele S, et al. Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. Oncol Rep 2004; 11: 453-458.
29. Findlay VJ, Turner DP, Moussa O, Watson DK. MicroRNA- mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res 2008; 68: 8499-8506.
30. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008.
31. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
32. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8: 871-878.
33. Oettgen P, Finger E, Sun Z, et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000; 275: 1216-1225.
34. Chen H, Nandi AK, Li X, Bieberich CJ. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 2002; 62: 338-340.
35. Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006; 12: 7279-7283.
36. Zhang M, Maass N, Magit D, Sager R. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor- suppressing gene maspin. Cell Growth Differ 1997; 8: 179-186.
37. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005; 24: 2474-2482.
38. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308.
39. Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 1996; 271: 23907-23913.
40. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009; 56(2): 275-286.
41. Attard G, Jameson C, Moreira J, et al. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J Clin Pathol 2009; 62: 373-376.
42. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68: 73-80.
43. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-188.
44. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 2009; 106: 12465-12470.
45. Makkonen H, Jaaskelainen T, Pitkanen-Arsiola T, et al. Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene 2008; 27: 4865-4876.
46. Cengiz E, Karaca B, Kucukzeybek Y, et al. Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 2009; 37: 1269-1277.
47. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
48. Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 2004; 32: 4358-4367.
49. Wang X, Deng H, Basu I, Zhu L. Induction of androgen receptor- dependent apoptosis in prostate cancer cells by the retinoblastoma protein. Cancer Res 2004; 64: 1377-1385.
50. Risek B, Bilski P, Rice AB, Schrader WT. Androgen receptor- mediated apoptosis is regulated by photoactivatable androgen receptor ligands. Mol Endocrinol 2008; 22: 2099-2115.
51. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-837.
52. Verger A, Duterque-Coquillaud M. When Ets transcription factors meet their partners. Bioessays 2002; 24: 362-370.
53. Li R, Pei H, Watson DK. Regulation of Ets function by protein - protein interactions. Oncogene 2000; 19: 6514-6523.
54. Sieweke MH, Tekotte H, Frampton J, Graf T. MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 1996; 85: 49-60.
55. Agoulnik IU, Weigel NL. Coactivator selective regulation of androgen receptor activity. Steroids 2009; 74: 669-674.
56. Myers E, Hill AD, Kelly G, et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005; 11: 2111-2122.
57. Nishida T, Terashima M, Fukami K, Yamada Y. PIASy controls ubiquitination-dependent proteasomal degradation of Ets-1. Biochem J 2007; 405: 481-488.
58. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008; 99: 33-76.
59. Church DR, Lee E, Thompson TA, et al. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate 2005; 63: 155-168.
60. Murakami Y, Yamagoe S, Noguchi K, et al. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx. J Biol Chem 2006; 281: 28113-28121.
61. Lin DY, Fang HI, Ma AH, et al. Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 2004; 24: 10529-10541.
62. Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69: 6131-6140.
63. Cho JY, Lee M, Ahn JM, et al. Proteomic analysis of a PDEF Ets transcription factor-interacting protein complex. J Proteome Res 2009; 8: 1327-1337.
64. Song H, Suehiro JI, Kanki Y, et al. A critical role for GATA3 in mediating Tie2 expression and function in large vessel endothelial cells. J Biol Chem 2009; 284: 29109-29124.
65. Qamar I, Park E, Gong EY, Lee HJ, Lee K. ARR19 (Androgen Receptor Corepressor of 19 kDa), an Antisteroidogenic Factor, Is Regulated by GATA-1 in Testicular Leydig Cells. J Biol Chem 2009; 284: 18021-18032.
66. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007; 67: 8388-8395.
67. Jiang AL, Hu XY, Zhang PJ, et al. Up-regulation of NKX3.1 expression and inhibition of LNCaP cell proliferation induced by an inhibitory element decoy. Acta Biochim Biophys Sin (Shanghai) 2005; 37: 335-40.
68. Turner EC, Kinsella BT. Transcriptional regulation of the human prostacyclin receptor gene is dependent on Sp1, PU.1 and Oct-1 in megakaryocytes and endothelial cells. J Mol Biol 2009; 386: 579-597.
69. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9: 1152-1159.
70. Gross M, Yang R, Top I, Gasper C, Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 2004; 23: 3059-3066.
71. Kaikkonen S, Jaaskelainen T, Karvonen U, et al. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol 2009; 23: 292-307.
72. Wang S, Yuan Y, Liao L, et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci USA 2009; 106: 151-156.
73. Al-azawi D, Ilroy MM, Kelly G, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 3021-3031.
74. Ji Z, Degerny C, Vintonenko N, et al. Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation. Oncogene 2007; 26: 395-406.
75. Roukens MG, Alloul-Ramdhani M, Vertegaal AC, et al. Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function. Mol Cell Biol 2008; 28: 2342-2357.
76. Salinas S, Briancon-Marjollet A, Bossis G, et al. SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol 2004; 165: 767-773.
77. Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
78. Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 1996; 271: 23907-23913.
79. Fletterick RJ. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen- independent prostate cancer. BJU Int 2005; 96 (Suppl 2): 2-9.
80. Wang Y, Feng L, Said M, et al. Analysis of the 2.0 A crystal structure of the protein-DNA complex of the human PDEF Ets domain bound to the prostate specific antigen regulatory site. Biochemistry 2005; 44: 7095-7106.
81. Lee GM, Donaldson LW, Pufall MA, et al. The structural and dynamic basis of Ets-1 DNA binding autoinhibition. J Biol Chem 2005; 280: 7088-7099.